TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06982534: Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 24 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,131,408

Rescue Site Savings

+$2,731,696

Unlock Full NCT06982534 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06982534 Rescue Dossier →